FDA Approves Ribociclib with an Aromatase Inhibitor and Ribociclib and Letrozole Co-pack for Early High-Risk Breast Cancer By Ogkologos - October 28, 2024 753 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy of ribociclib with a non-steroidal aromatase inhibitor is based on the results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Sacituzumab tirumotecan plus pembrolizumab significantly prolongs progression-free survival in advanced non-small... October 25, 2026 Metastatic Colorectal Cancer May Spread Early in the Disease, Study Finds July 22, 2019 Long-Term Outcomes in Patients with Metastatic Melanoma Treated with Anti-PD1 Therapy... October 28, 2021 Daughter Surprises Terminally Ill Mom With Graduation Ceremony In Hospital Room. May 16, 2019 Load more HOT NEWS Additional Translations of the ESMO Patient Guides Now Available in the Croatian Banking on breakthroughs for children and young people Breaking News: The Healthcare Marketplace Re-opens TODAY! Young Mom-of-Three Learns She Has Stage 4 Breast Cancer, 5 Days...
